GVM ±R in Patients With Relapsed or Refractory Aggressive NHL.
Conditions: Peripheral T Cell Lymphoma; Diffuse Large B-cell Lymphoma Interventions: Drug: GVM ±R regimen Sponsors: Qiu Lugui Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 6, 2024 Category: Research Source Type: clinical trials

Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T
Conditions: T-cell Lymphoma Interventions: Biological: hNeo-T; Drug: Cyclophosphamide; Drug: Fludarabine Sponsors: BGI, China Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 25, 2024 Category: Research Source Type: clinical trials

Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL
Conditions: Angioimmunoblastic T-cell Lymphoma Interventions: Drug: mitoxantrone liposome 16 and azacitidine; Drug: mitoxantrone liposome 18 and azacitidine; Drug: mitoxantrone liposome 20 and azacitidine Sponsors: Huijing Wu; Beijing Xisike Clinical Oncology Research Foundation; CSPC Pharmaceutical Group Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 25, 2024 Category: Research Source Type: clinical trials

Chi-GVM Regimen for the Treatment of R/R PTCL
Conditions: Relapsed/Refractory Peripheral T-cell Lymphoma Interventions: Drug: Chi-GVM Sponsors: The First Affiliated Hospital with Nanjing Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 18, 2024 Category: Research Source Type: clinical trials

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Conditions: CD30-Positive Diffuse Large B-Cell Lymphoma; Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type; Anaplastic Large Cell Lymphoma, ALK-Positive; Peripheral T-cell Lymphoma; Anaplastic Large Cell Lymphoma, ALK-negative; Non-Hodgkin Lymphoma; Hodgkin Lymphoma Interventions: Biological: C7R.CD30.CAR-EBVST cells Sponsors: Baylor College of Medicine; The Methodist Hospital Research Institute; Center for Cell and Gene Therapy, Baylor College of Medicine Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 20, 2023 Category: Research Source Type: clinical trials

Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Angioimmunoblastic T Cell Lymphoma
Conditions: Relapsed Angioimmunoblastic T-Cell Lymphoma; Refractory Angioimmunoblastic T-cell Lymphoma Interventions: Drug: Azacytidine plus CAOLD regimen Sponsors: Navy General Hospital, Beijing; Chinese PLA General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 19, 2023 Category: Research Source Type: clinical trials

A Study of SHR2554 With Chemotherapy in Treatment-na ïve Patients With Peripheral T-cell Lymphoma
Conditions: Peripheral T-cell Lymphoma Interventions: Drug: SHR2554/CHOP; Drug: SHR2554/CHOEP Sponsors: Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 18, 2023 Category: Research Source Type: clinical trials

Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma
Conditions: Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-Cell Lymphoma Interventions: Drug: Pembrolizumab IV infusion Q3W, with daily oral Olaparib. Sponsors: National Cancer Centre, Singapore; Merck Sharp& Dohme LLC; National Medical Research Council (NMRC), Singapore Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 7, 2023 Category: Research Source Type: clinical trials

Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
Conditions: Peripheral T Cell Lymphoma; Relapsed Peripheral T-Cell Lymphoma; Refractory T-Cell Lymphoma Interventions: Drug: Chidamide combined with Duvillisib Sponsors: The First Affiliated Hospital of Xiamen University; Fujian Cancer Hospital; Zhangzhou Affiliated Hospital of Fujian Medical University; Dongguan People ' s Hospital; Huizhou Municipal Central Hospital; The First Affiliated Hospital with Nanjing Medical University; Sun Yat-sen University; Shanxi Province Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2023 Category: Research Source Type: clinical trials

ASCT Versus Chemotherapy as First-Line Consolidation Therapy inT-Cell Lymphoma
Conditions: T-cell Lymphoma Adults Interventions: Drug: consolidation with ASCT Sponsors: Huazhong University of Science and Technology; Peking University People ' s Hospital; Ruijin Hospital; West China Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 29, 2023 Category: Research Source Type: clinical trials

HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
Conditions: Cutaneous T-Cell Lymphoma/Mycosis Fungoides Interventions: Drug: Hypericin; Drug: Mechlorethamine Topical Gel Sponsors: Soligenix Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 28, 2023 Category: Research Source Type: clinical trials

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Conditions: Hematologic Malignancy; Leukemia; Lymphoma; Acute Lymphocytic Leukemia; ALL; Acute Myelogenous Leukemia; AML; Chronic Myelogenous Leukemia; CML; Myeloproliferative Neoplasm; Non Hodgkin Lymphoma; Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma; Follicular Lymphoma; Burkitt Lymphoma; T-cell Lymphoma; B Cell Lymphoma; Peripheral T Cell Lymphoma; Cutaneous B-Cell Lymphoma Interventions: Other: 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care. Sponsors: Children ' s Hospit...
Source: ClinicalTrials.gov - November 14, 2023 Category: Research Source Type: clinical trials

SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma
Conditions: T-cell Lymphoma Patients After First-line Treatment Failure Interventions: Drug: SHR2554; Chidamide analog tablets; Drug: SHR2554 analog tablets; Chidamide Sponsors: Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 8, 2023 Category: Research Source Type: clinical trials

Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma: a Multicenter Observational Study
Conditions: Cutaneous T Cell Lymphoma; Cutaneous T-Cell Lymphoma/Mycosis Fungoides; Cutaneous T-Cell Lymphoma/Sezary Syndrome Sponsors: Fondazione Italiana Linfomi - ETS Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 2, 2023 Category: Research Source Type: clinical trials

Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma
Conditions: Cutaneous T Cell Lymphoma; Cutaneous T-Cell Lymphoma/Mycosis Fungoides; Cutaneous T-Cell Lymphoma/Sezary Syndrome Sponsors: Fondazione Italiana Linfomi - ETS Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 2, 2023 Category: Research Source Type: clinical trials